ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 709,75
0,98%
Dow Jones
43 487,83
0,78%
DAX
20 903,39
1,31%
Brent Oil
80,005
0,00%
Bitcoin
104 398,64
0,26%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. EyePoint Pharmaceuticals Inc (EYPT) Cours

EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc (EYPT)

NASDAQ
7,48
0,21
(2,89%)
Fermé 18 Janvier 10:00PM
Retardé de 15 minutes
7,48
-0,01
(-0,13%)
Après les heures de négociation: 11:13PM
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
7,48
Prix Achat
7,30
Prix Vente
7,48
Volume échangé
564 887
7,15 Fourchette du Jour 7,52
6,91 Plage de 52 semaines 30,99
Cap du marché
510,518M
Clôture Veille
7,27
Ouverture
7,36
Dernière Transaction
4
@
7.48
Dernière heure de transaction
Volume financier
US$ 4 169 903
VWAP
7,3818
Volume moyen (3 m)
1 026 786
Actions en circulation
68 251 031
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-7,22
Bénéfice par action (BPA)
-1,04
Chiffre d'affairess
46,02M
Bénéfice net
-70,8M

À propos de EyePoint Pharmaceuticals Inc

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on us... EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Show more

Secteur
Lab Analytical Instruments
Industrie
Lab Analytical Instruments
Site Web
www.eyepointpharma.com
Siège social
Wilmington, Delaware, USA
Fondé
-
EyePoint Pharmaceuticals Inc est coté dans le secteur Lab Analytical Instruments de la NASDAQ avec le ticker EYPT. Le dernier cours de clôture d'EyePoint Pharmaceuticals était de US$7,27. Au cours de la dernière année, les actions de EyePoint Pharmaceuticals ont été négociées dans une fourchette de prix de US$ 6,91 à US$ 30,99.

EyePoint Pharmaceuticals compte actuellement 68 251 031 actions en circulation. La capitalisation boursière d'EyePoint Pharmaceuticals est de US$496,18 million. EyePoint Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -7.22.

Flux d'options EyePoint Pharmaceuticals (EYPT)

Voir le flux d'options complet

Flux global

Haussier

Prime nette

119k

Calls / Puts

100,00%

Ach. / Vent.

100,00%

OTM / ITM

100,00%

Sweeps Ratio

0,00%

EYPT Dernières nouvelles

Plus de nouvelles

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...

16 Janvier 2025
GlobeNewswire Inc.

Form 8-K - Current report

13 Janvier 2025
Edgar (US Regulatory)

EyePoint Provides Company Update and Anticipated Development Milestones for 2025

– Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of schedule – – Full data for Phase 2...

13 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

08 Janvier 2025
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

08 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

08 Janvier 2025
Edgar (US Regulatory)

EyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of Directors

WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the...

08 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

07 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

07 Janvier 2025
Edgar (US Regulatory)
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-1.52-16.888888888999.017.158758457.59766826CS
40.486.8571428571479.49996.919404437.68456483CS
12-2.11-22.00208550579.5913.9856.9110267869.2909793CS
26-2.67-26.305418719210.1513.9856.917831109.11942518CS
52-14.22-65.529953917121.730.996.9192721014.10600059CS
156-2.57-25.572139303510.0530.992.1963904512.70931416CS
2605.74329.8850574711.7430.990.35117104538.51325408CS

EYPT - Frequently Asked Questions (FAQ)

What is the current EyePoint Pharmaceuticals share price?
The current share price of EyePoint Pharmaceuticals is US$ 7,48
How many EyePoint Pharmaceuticals shares are in issue?
EyePoint Pharmaceuticals has 68 251 031 shares in issue
What is the market cap of EyePoint Pharmaceuticals?
The market capitalisation of EyePoint Pharmaceuticals is USD 496,18M
What is the 1 year trading range for EyePoint Pharmaceuticals share price?
EyePoint Pharmaceuticals has traded in the range of US$ 6,91 to US$ 30,99 during the past year
What is the PE ratio of EyePoint Pharmaceuticals?
The price to earnings ratio of EyePoint Pharmaceuticals is -7,22
What is the cash to sales ratio of EyePoint Pharmaceuticals?
The cash to sales ratio of EyePoint Pharmaceuticals is 11,11
What is the reporting currency for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals reports financial results in USD
What is the latest annual turnover for EyePoint Pharmaceuticals?
The latest annual turnover of EyePoint Pharmaceuticals is USD 46,02M
What is the latest annual profit for EyePoint Pharmaceuticals?
The latest annual profit of EyePoint Pharmaceuticals is USD -70,8M
What is the registered address of EyePoint Pharmaceuticals?
The registered address for EyePoint Pharmaceuticals is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the EyePoint Pharmaceuticals website address?
The website address for EyePoint Pharmaceuticals is www.eyepointpharma.com
Which industry sector does EyePoint Pharmaceuticals operate in?
EyePoint Pharmaceuticals operates in the LAB ANALYTICAL INSTRUMENTS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
BTCTBTC Digital Ltd
US$ 8,2697
(73,73%)
61,45M
BDMDBaird Medical Investment Holdings Ltd
US$ 8,80
(62,36%)
18,63M
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
NUKKNukkleus Inc
US$ 29,97
(45,98%)
19,09M
GSITGSI Technology
US$ 3,97
(44,36%)
87,7M
DOGZDogness International Corporation
US$ 18,23
(-58,77%)
740,45k
ORKTOrangeKloud Technology Inc
US$ 3,02
(-24,88%)
21,08M
PMAXPowell Max Ltd
US$ 0,6364
(-23,31%)
4,17M
LGCBLinkage Global Inc
US$ 0,2876
(-22,27%)
890,66k
YYAIConnexa Sports Technologies Inc
US$ 0,8299
(-20,20%)
602,48k
CRKNCrown Electrokinetics Corporation
US$ 0,1235
(54,96%)
764,86M
GCTKGlucoTrack Inc
US$ 0,0852
(15,45%)
465,22M
RIMEAlgorhythm Holdings Inc
US$ 0,0406
(-4,02%)
387,23M
TGLTreasure Global Inc
US$ 0,2459
(14,75%)
267,1M
NVDANVIDIA Corporation
US$ 137,71
(3,10%)
201,4M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
EYPT
EyePoint Pharmaceuticals
BIT
F15922
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés